Sanofi's next-gen rabies shot VaxRabeo scores EU approval
Sanofi won European Commission approval for VaxRabeo, a next-generation rabies vaccine cleared for pre- and post-exposure use in all age groups in the EU. It follows a US FDA nod for Infilbray in Type 3 Gaucher disease. Shares closed at €86.25, but one Simply Wall St community narrative pegs fair value at €72.23 — roughly 19% below where Sanofi trades.
- Original source: finance.yahoo.com.
- The source published it on Nov 19, 2026 at 3:16 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Sanofi just picked up European Commission approval for VaxRabeo, a next-generation rabies vaccine cleared for both pre-exposure and post-exposure use in every age group across the EU. It's the French drugmaker's second regulatory win in a short stretch.
The other came from the US FDA, which green-lit Infilbray for Type 3 Gaucher disease. Sanofi is also preparing for a leadership change in R&D starting January 2027.
The stock has been moving. Sanofi last closed at €86.25, with a 30-day share price return of 21.46% and a 90-day return of 10.88%, even as the 1-day return slipped slightly. Over longer horizons, the 1-year total shareholder return sits at 5.97% and the 5-year at 22.40%.
Not everyone is convinced the price matches the progress. A community narrative on Simply Wall St written by investor Szock sets fair value at €72.23, which would make Sanofi about 19% overvalued at its current level. Szock frames the company as a mix of valuation appeal, income and operational momentum, noting the shares traded in a range of roughly €76 to €77 in recent months and sit well below earlier highs.
The bull case rests on expectations that analysts set fair value noticeably higher and a moderate price-to-earnings ratio on forecast profits. The bear case has teeth too: the narrative cracks if key drugs meet faster-than-expected competition or if regulatory setbacks slow the pipeline.
TopicsSanofi · VaxRabeo · Infilbray · European Commission · US FDA · Simply Wall St · Szock · ENXTPA:SAN
Source: finance.yahoo.com
Written by AI from verified reporting.
More stories
- Health & science reuters.com Caught by @mimi💕💕 1 viewAbbVie Bets Up to $2.54B on Disco's Next-Gen Cancer Drugs
- Health & science fnob.it 1 viewTenK10K maps 5 million immune cells, linking DNA variants to 16 diseases
- Health & science trtworld.com Caught by @pz09253 0 viewsFrance lifts bird flu alert to maximum level across mainland
- Health & science news24.com.au 0 viewsActinogen trial: Alzheimer's drug slows decline by 30pc in over-75s

